Galmed Pharmaceuticals Ltd. (GLMD) 10-Year Financial Performance & Capital Metrics

GLMD • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutGalmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Show more

Revenue $0
EBITDA -$6M -182.3%
Net Income -$8M -8.8%
EPS (Diluted) -8.08 +73.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -49.77% +1.7%
ROIC -41.42% -183.0%
Debt/Equity -
Interest Coverage -418.53 -161.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-48.26%

EPS CAGR

10Y-

5Y-

3Y-

TTM-2412%

ROCE

10Y Avg-48.65%

5Y Avg-41.39%

3Y Avg-22.22%

Latest-41.57%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	467K	1.08M	2.04M	0	0	0	0	0	0
Revenue Growth %	-	-	1.32%	0.88%	-1%	-	-	-	-	-
Cost of Goods Sold+	50K	0	0	0	35K	39K	42K	35K	31K	83K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-50K	467K	1.08M	2.04M	-35K	-39K	-42K	-35K	-31K	-83K
Gross Margin %	-	1%	1%	1%	-	-	-	-	-	-
Gross Profit Growth %	-	10.34%	1.32%	0.88%	-1.02%	-0.11%	-0.08%	0.17%	0.11%	-1.68%
Operating Expenses+	10.88M	17.35M	13.45M	12.75M	22.38M	30.21M	32.88M	17.65M	-7.49M	6.2M
OpEx % of Revenue	-	37.15%	12.4%	6.26%	-	-	-	-	-	-
Selling, General & Admin	3.25M	3.08M	3.8M	4.44M	4.2M	4.13M	5.66M	4.66M	3.92M	3.3M
SG&A % of Revenue	-	6.59%	3.5%	2.18%	-	-	-	-	-	-
Research & Development	7.63M	14.27M	9.65M	8.31M	18.18M	26.08M	27.22M	12.99M	3.57M	2.98M
R&D % of Revenue	-	30.56%	8.89%	4.08%	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	-14.98M	-83K
Operating Income+	-10.88M	-16.88M	-12.36M	-10.71M	-22.38M	-30.21M	-32.88M	-17.65M	7.49M	-6.28M
Operating Margin %	-	-36.15%	-11.4%	-5.26%	-	-	-	-	-	-
Operating Income Growth %	-0.19%	-0.55%	0.27%	0.13%	-1.09%	-0.35%	-0.09%	0.46%	1.42%	-1.84%
EBITDA+	-10.82M	-16.71M	-12.13M	-10.33M	-22.34M	-30.17M	-32.84M	-17.62M	7.52M	-6.2M
EBITDA Margin %	-	-35.79%	-11.18%	-5.07%	-	-	-	-	-	-
EBITDA Growth %	-0.19%	-0.54%	0.27%	0.15%	-1.16%	-0.35%	-0.09%	0.46%	1.43%	-1.82%
D&A (Non-Cash Add-back)	50K	169K	239K	387K	35K	39K	42K	35K	31K	83K
EBIT	-10.88M	-16.88M	-12.36M	-10.71M	-22.38M	-30.21M	-32.88M	-17.65M	-6.9M	-7.5M
Net Interest Income+	0	315K	153K	917K	1.88M	1.16M	519K	82K	364K	488K
Interest Income	253K	35K	65K	959K	1.92M	1.19M	562K	297K	375K	503K
Interest Expense	0	67K	49K	42K	33K	31K	43K	215K	11K	15K
Other Income/Expense	253K	35K	65K	934K	1.92M	1.44M	414K	-215K	-14.4M	-1.24M
Pretax Income+	-10.62M	-16.85M	-12.3M	-9.78M	-20.46M	-28.77M	-32.47M	-17.87M	-6.91M	-7.52M
Pretax Margin %	-	-36.07%	-11.34%	-4.8%	-	-	-	-	-	-
Income Tax+	0	106K	0	75K	0	0	0	0	0	0
Effective Tax Rate %	1%	1.01%	1%	1.01%	0.91%	0.96%	0.98%	1.04%	1%	1%
Net Income+	-10.62M	-16.95M	-12.3M	-9.86M	-18.54M	-27.61M	-31.95M	-18.57M	-6.91M	-7.52M
Net Margin %	-	-36.3%	-11.34%	-4.84%	-	-	-	-	-	-
Net Income Growth %	-0.17%	-0.6%	0.27%	0.2%	-0.88%	-0.49%	-0.16%	0.42%	0.63%	-0.09%
Net Income (Continuing)	-10.62M	-16.95M	-12.3M	-9.86M	-20.46M	-28.77M	-32.47M	-17.87M	-6.91M	-7.52M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-14.35	-22.36	-14.77	-8.15	-13.17	-19.46	-19.48	-11.08	-29.95	-8.08
EPS Growth %	-0.08%	-0.56%	0.34%	0.45%	-0.62%	-0.48%	-0%	0.43%	-1.7%	0.73%
EPS (Basic)	-14.35	-22.36	-14.77	-8.15	-13.17	-19.46	-19.48	-11.08	-30.05	-8.08
Diluted Shares Outstanding	740.03K	758.31K	832.49K	1.21M	1.41M	1.42M	1.64M	1.68M	230.79K	930.82K
Basic Shares Outstanding	740.03K	758.31K	832.49K	1.21M	1.41M	1.42M	1.64M	1.68M	230K	930.82K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	23.38M	15.73M	19.15M	90.41M	76.43M	51.81M	36.05M	14.72M	13.24M	16.12M
Cash & Short-Term Investments	23M	15.45M	19M	90.19M	75.49M	50.89M	34.81M	13.79M	12.64M	15.33M
Cash Only	4.16M	3.1M	13.02M	24.16M	15.93M	6.95M	2.88M	2.02M	2.86M	4.65M
Short-Term Investments	18.84M	12.35M	5.98M	66.03M	59.56M	43.94M	31.93M	11.77M	9.78M	10.68M
Accounts Receivable	109K	284K	155K	51K	226K	66K	79K	0	165K	209K
Days Sales Outstanding	-	221.97	52.14	9.13	-	-	-	-	-	-
Inventory	-270K	-254K	-100K	0	0	0	0	114K	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	1.19K	-	-
Other Current Assets	0	0	0	0	112K	113K	114K	0	117K	121K
Total Non-Current Assets+	883K	718K	491K	194K	709K	570K	551K	1.84M	3.39M	2.38M
Property, Plant & Equipment	883K	718K	491K	194K	709K	570K	551K	337K	125K	0
Fixed Asset Turnover	-	0.65x	2.21x	10.51x	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	1.5M	3.27M	2.12M
Other Non-Current Assets	0	0	0	0	0	0	0	0	0	257K
Total Assets+	24.26M	16.45M	19.64M	90.6M	77.14M	52.38M	36.6M	16.56M	16.63M	18.5M
Asset Turnover	-	0.03x	0.06x	0.02x	-	-	-	-	-	-
Asset Growth %	-0.26%	-0.32%	0.19%	3.61%	-0.15%	-0.32%	-0.3%	-0.55%	0%	0.11%
Total Current Liabilities+	2.54M	4.58M	3.85M	2.71M	6.93M	8.01M	5.88M	3.09M	2.75M	2.17M
Accounts Payable	2.26M	3.12M	2.28M	1.81M	6M	7.05M	4.87M	2.56M	1.88M	1.31M
Days Payables Outstanding	16.49K	-	-	-	62.56K	65.94K	42.33K	26.7K	22.12K	5.75K
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	1000K	538K	0	0	0	0	-171K	0	0
Other Current Liabilities	0	363K	1.03M	892K	935K	966K	1.01M	363K	571K	603K
Current Ratio	9.20x	3.44x	4.98x	33.41x	11.02x	6.47x	6.13x	4.76x	4.81x	7.42x
Quick Ratio	9.31x	3.49x	5.00x	33.41x	11.02x	6.47x	6.13x	4.72x	4.81x	7.42x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	177K	796K	0	0	352K	216K	229K	44K	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	352K	216K	229K	44K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	177K	267K	0	0	0	0	0	0	0	0
Total Liabilities	2.72M	5.38M	3.85M	2.71M	7.29M	8.23M	6.11M	3.14M	2.75M	2.17M
Total Debt+	0	0	0	0	352K	216K	229K	44K	41K	0
Net Debt	-4.16M	-3.1M	-13.02M	-24.16M	-15.58M	-6.73M	-2.65M	-1.97M	-2.82M	-4.65M
Debt / Equity	-	-	-	-	0.01x	0.00x	0.01x	0.00x	0.00x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	0.01x	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-0.37x	-
Interest Coverage	-	-251.97x	-252.33x	-255.12x	-678.06x	-974.52x	-764.67x	-82.10x	681.09x	-418.53x
Total Equity+	21.55M	11.07M	15.79M	87.89M	69.85M	44.15M	30.5M	13.42M	13.88M	16.33M
Equity Growth %	-0.31%	-0.49%	0.43%	4.56%	-0.21%	-0.37%	-0.31%	-0.56%	0.03%	0.18%
Book Value per Share	29.11	14.60	18.97	72.69	49.62	31.12	18.60	8.01	60.14	17.54
Total Shareholders' Equity	21.55M	11.07M	15.79M	87.89M	69.85M	44.15M	30.5M	13.42M	13.88M	16.33M
Common Stock	32K	34K	40K	58K	58K	58K	70K	70K	209K	742K
Retained Earnings	-47.37M	-64.32M	-76.62M	-86.47M	-106.94M	-135.71M	-168.17M	-186.04M	-192.95M	-200.47M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-206K	-85K	-7K	-11K	35K	272K	-171K	-745K	-454K	-416K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.47M	-12.13M	-12.07M	-9.02M	-14.94M	-26.29M	-32.89M	-18.5M	-6.14M	-5.88M
Operating CF Margin %	-	-25.97%	-11.12%	-4.43%	-	-	-	-	-	-
Operating CF Growth %	0.08%	-0.43%	0.01%	0.25%	-0.66%	-0.76%	-0.25%	0.44%	0.67%	0.04%
Net Income	-10.62M	-16.95M	-12.3M	-9.86M	-20.46M	-28.77M	-32.47M	-17.87M	-6.91M	-7.52M
Depreciation & Amortization	50K	169K	239K	387K	35K	39K	42K	35K	31K	83K
Stock-Based Compensation	970K	1.63M	1.39M	1.78M	2.23M	2.07M	1.89M	1.3M	892K	531K
Deferred Taxes	-920K	-1.4M	164K	12K	-114K	-437K	84K	0	0	0
Other Non-Cash Items	1.06M	1.67M	-167K	-144K	-63K	-285K	13K	485K	-280K	1.75M
Working Capital Changes	986K	2.75M	-1.4M	-1.21M	3.44M	1.1M	-2.45M	-2.45M	132K	-728K
Change in Receivables	-214K	95K	129K	-63K	-609K	15K	-313K	300K	345K	-192K
Change in Inventory	39K	81K	671K	-142K	609K	-15K	313K	-300K	0	0
Change in Payables	1.38M	863K	-846K	-462K	4.18M	1.05M	-2.17M	-2.31M	-681K	-571K
Cash from Investing+	-11.11M	6.34M	6.44M	-60.02M	6.68M	16.54M	11.46M	17.56M	800K	-1.11M
Capital Expenditures	-159K	-17K	-21K	-90K	-12K	-44K	-11K	-4K	0	0
CapEx % of Revenue	-	0.04%	0.02%	0.04%	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	6M	13K	9K	-6.08M	-21.8M	24.94M	-1K	17.57K	0	-250K
Cash from Financing+	0	4.73M	15.55M	80.18M	143K	768K	17.37M	70K	6.18M	8.79M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	255K	530K	1.03M	143K	61K	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.63M	-12.15M	-12.09M	-9.11M	-14.95M	-26.33M	-32.9M	-18.5M	-6.14M	-5.88M
FCF Margin %	-	-26.01%	-11.14%	-4.47%	-	-	-	-	-	-
FCF Growth %	0.14%	-0.41%	0%	0.25%	-0.64%	-0.76%	-0.25%	0.44%	0.67%	0.04%
FCF per Share	-11.67	-16.02	-14.52	-7.54	-10.62	-18.56	-20.06	-11.04	-26.59	-6.32
FCF Conversion (FCF/Net Income)	0.80x	0.72x	0.98x	0.92x	0.81x	0.95x	1.03x	1.00x	0.89x	0.78x
Interest Paid	0	382K	0	865K	0	0	0	0	0	0
Taxes Paid	0	106K	0	75K	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-40.12%	-103.94%	-91.54%	-19.01%	-23.51%	-48.44%	-85.59%	-84.57%	-50.63%	-49.77%
Return on Invested Capital (ROIC)	-65.09%	-99.83%	-172.49%	-24.17%	-28.44%	-49.42%	-75.57%	-67.38%	49.92%	-41.42%
Gross Margin	-	100%	100%	100%	-	-	-	-	-	-
Net Margin	-	-3630.19%	-1133.55%	-483.61%	-	-	-	-	-	-
Debt / Equity	-	-	-	-	0.01x	0.00x	0.01x	0.00x	0.00x	-
Interest Coverage	-	-251.97x	-252.33x	-255.12x	-678.06x	-974.52x	-764.67x	-82.10x	681.09x	-418.53x
FCF Conversion	0.80x	0.72x	0.98x	0.92x	0.81x	0.95x	1.03x	1.00x	0.89x	0.78x
Revenue Growth	-	-	132.33%	87.83%	-100%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Galmed Pharmaceuticals Ltd. (GLMD) grew revenue by 0.0% over the past year. Growth has been modest.

Galmed Pharmaceuticals Ltd. (GLMD) reported a net loss of $8.7M for fiscal year 2024.

Dividend & Returns

Galmed Pharmaceuticals Ltd. (GLMD) has a return on equity (ROE) of -49.8%. Negative ROE indicates the company is unprofitable.

Galmed Pharmaceuticals Ltd. (GLMD) had negative free cash flow of $5.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Galmed Pharmaceuticals Ltd. (GLMD) 10-Year Financial Performance & Capital Metrics

GLMD • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

Revenue $0
EBITDA -$6M -182.3%
Net Income -$8M -8.8%
EPS (Diluted) -8.08 +73.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -49.77% +1.7%
ROIC -41.42% -183.0%
Debt/Equity -
Interest Coverage -418.53 -161.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-48.26%

EPS CAGR

10Y-

5Y-

3Y-

TTM-2412%

ROCE

10Y Avg-48.65%

5Y Avg-41.39%

3Y Avg-22.22%

Latest-41.57%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	467K	1.08M	2.04M	0	0	0	0	0	0
Revenue Growth %	-	-	1.32%	0.88%	-1%	-	-	-	-	-
Cost of Goods Sold+	50K	0	0	0	35K	39K	42K	35K	31K	83K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-50K	467K	1.08M	2.04M	-35K	-39K	-42K	-35K	-31K	-83K
Gross Margin %	-	1%	1%	1%	-	-	-	-	-	-
Gross Profit Growth %	-	10.34%	1.32%	0.88%	-1.02%	-0.11%	-0.08%	0.17%	0.11%	-1.68%
Operating Expenses+	10.88M	17.35M	13.45M	12.75M	22.38M	30.21M	32.88M	17.65M	-7.49M	6.2M
OpEx % of Revenue	-	37.15%	12.4%	6.26%	-	-	-	-	-	-
Selling, General & Admin	3.25M	3.08M	3.8M	4.44M	4.2M	4.13M	5.66M	4.66M	3.92M	3.3M
SG&A % of Revenue	-	6.59%	3.5%	2.18%	-	-	-	-	-	-
Research & Development	7.63M	14.27M	9.65M	8.31M	18.18M	26.08M	27.22M	12.99M	3.57M	2.98M
R&D % of Revenue	-	30.56%	8.89%	4.08%	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	-14.98M	-83K
Operating Income+	-10.88M	-16.88M	-12.36M	-10.71M	-22.38M	-30.21M	-32.88M	-17.65M	7.49M	-6.28M
Operating Margin %	-	-36.15%	-11.4%	-5.26%	-	-	-	-	-	-
Operating Income Growth %	-0.19%	-0.55%	0.27%	0.13%	-1.09%	-0.35%	-0.09%	0.46%	1.42%	-1.84%
EBITDA+	-10.82M	-16.71M	-12.13M	-10.33M	-22.34M	-30.17M	-32.84M	-17.62M	7.52M	-6.2M
EBITDA Margin %	-	-35.79%	-11.18%	-5.07%	-	-	-	-	-	-
EBITDA Growth %	-0.19%	-0.54%	0.27%	0.15%	-1.16%	-0.35%	-0.09%	0.46%	1.43%	-1.82%
D&A (Non-Cash Add-back)	50K	169K	239K	387K	35K	39K	42K	35K	31K	83K
EBIT	-10.88M	-16.88M	-12.36M	-10.71M	-22.38M	-30.21M	-32.88M	-17.65M	-6.9M	-7.5M
Net Interest Income+	0	315K	153K	917K	1.88M	1.16M	519K	82K	364K	488K
Interest Income	253K	35K	65K	959K	1.92M	1.19M	562K	297K	375K	503K
Interest Expense	0	67K	49K	42K	33K	31K	43K	215K	11K	15K
Other Income/Expense	253K	35K	65K	934K	1.92M	1.44M	414K	-215K	-14.4M	-1.24M
Pretax Income+	-10.62M	-16.85M	-12.3M	-9.78M	-20.46M	-28.77M	-32.47M	-17.87M	-6.91M	-7.52M
Pretax Margin %	-	-36.07%	-11.34%	-4.8%	-	-	-	-	-	-
Income Tax+	0	106K	0	75K	0	0	0	0	0	0
Effective Tax Rate %	1%	1.01%	1%	1.01%	0.91%	0.96%	0.98%	1.04%	1%	1%
Net Income+	-10.62M	-16.95M	-12.3M	-9.86M	-18.54M	-27.61M	-31.95M	-18.57M	-6.91M	-7.52M
Net Margin %	-	-36.3%	-11.34%	-4.84%	-	-	-	-	-	-
Net Income Growth %	-0.17%	-0.6%	0.27%	0.2%	-0.88%	-0.49%	-0.16%	0.42%	0.63%	-0.09%
Net Income (Continuing)	-10.62M	-16.95M	-12.3M	-9.86M	-20.46M	-28.77M	-32.47M	-17.87M	-6.91M	-7.52M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-14.35	-22.36	-14.77	-8.15	-13.17	-19.46	-19.48	-11.08	-29.95	-8.08
EPS Growth %	-0.08%	-0.56%	0.34%	0.45%	-0.62%	-0.48%	-0%	0.43%	-1.7%	0.73%
EPS (Basic)	-14.35	-22.36	-14.77	-8.15	-13.17	-19.46	-19.48	-11.08	-30.05	-8.08
Diluted Shares Outstanding	740.03K	758.31K	832.49K	1.21M	1.41M	1.42M	1.64M	1.68M	230.79K	930.82K
Basic Shares Outstanding	740.03K	758.31K	832.49K	1.21M	1.41M	1.42M	1.64M	1.68M	230K	930.82K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	23.38M	15.73M	19.15M	90.41M	76.43M	51.81M	36.05M	14.72M	13.24M	16.12M
Cash & Short-Term Investments	23M	15.45M	19M	90.19M	75.49M	50.89M	34.81M	13.79M	12.64M	15.33M
Cash Only	4.16M	3.1M	13.02M	24.16M	15.93M	6.95M	2.88M	2.02M	2.86M	4.65M
Short-Term Investments	18.84M	12.35M	5.98M	66.03M	59.56M	43.94M	31.93M	11.77M	9.78M	10.68M
Accounts Receivable	109K	284K	155K	51K	226K	66K	79K	0	165K	209K
Days Sales Outstanding	-	221.97	52.14	9.13	-	-	-	-	-	-
Inventory	-270K	-254K	-100K	0	0	0	0	114K	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	1.19K	-	-
Other Current Assets	0	0	0	0	112K	113K	114K	0	117K	121K
Total Non-Current Assets+	883K	718K	491K	194K	709K	570K	551K	1.84M	3.39M	2.38M
Property, Plant & Equipment	883K	718K	491K	194K	709K	570K	551K	337K	125K	0
Fixed Asset Turnover	-	0.65x	2.21x	10.51x	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	1.5M	3.27M	2.12M
Other Non-Current Assets	0	0	0	0	0	0	0	0	0	257K
Total Assets+	24.26M	16.45M	19.64M	90.6M	77.14M	52.38M	36.6M	16.56M	16.63M	18.5M
Asset Turnover	-	0.03x	0.06x	0.02x	-	-	-	-	-	-
Asset Growth %	-0.26%	-0.32%	0.19%	3.61%	-0.15%	-0.32%	-0.3%	-0.55%	0%	0.11%
Total Current Liabilities+	2.54M	4.58M	3.85M	2.71M	6.93M	8.01M	5.88M	3.09M	2.75M	2.17M
Accounts Payable	2.26M	3.12M	2.28M	1.81M	6M	7.05M	4.87M	2.56M	1.88M	1.31M
Days Payables Outstanding	16.49K	-	-	-	62.56K	65.94K	42.33K	26.7K	22.12K	5.75K
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	1000K	538K	0	0	0	0	-171K	0	0
Other Current Liabilities	0	363K	1.03M	892K	935K	966K	1.01M	363K	571K	603K
Current Ratio	9.20x	3.44x	4.98x	33.41x	11.02x	6.47x	6.13x	4.76x	4.81x	7.42x
Quick Ratio	9.31x	3.49x	5.00x	33.41x	11.02x	6.47x	6.13x	4.72x	4.81x	7.42x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	177K	796K	0	0	352K	216K	229K	44K	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	352K	216K	229K	44K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	177K	267K	0	0	0	0	0	0	0	0
Total Liabilities	2.72M	5.38M	3.85M	2.71M	7.29M	8.23M	6.11M	3.14M	2.75M	2.17M
Total Debt+	0	0	0	0	352K	216K	229K	44K	41K	0
Net Debt	-4.16M	-3.1M	-13.02M	-24.16M	-15.58M	-6.73M	-2.65M	-1.97M	-2.82M	-4.65M
Debt / Equity	-	-	-	-	0.01x	0.00x	0.01x	0.00x	0.00x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	0.01x	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-0.37x	-
Interest Coverage	-	-251.97x	-252.33x	-255.12x	-678.06x	-974.52x	-764.67x	-82.10x	681.09x	-418.53x
Total Equity+	21.55M	11.07M	15.79M	87.89M	69.85M	44.15M	30.5M	13.42M	13.88M	16.33M
Equity Growth %	-0.31%	-0.49%	0.43%	4.56%	-0.21%	-0.37%	-0.31%	-0.56%	0.03%	0.18%
Book Value per Share	29.11	14.60	18.97	72.69	49.62	31.12	18.60	8.01	60.14	17.54
Total Shareholders' Equity	21.55M	11.07M	15.79M	87.89M	69.85M	44.15M	30.5M	13.42M	13.88M	16.33M
Common Stock	32K	34K	40K	58K	58K	58K	70K	70K	209K	742K
Retained Earnings	-47.37M	-64.32M	-76.62M	-86.47M	-106.94M	-135.71M	-168.17M	-186.04M	-192.95M	-200.47M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-206K	-85K	-7K	-11K	35K	272K	-171K	-745K	-454K	-416K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.47M	-12.13M	-12.07M	-9.02M	-14.94M	-26.29M	-32.89M	-18.5M	-6.14M	-5.88M
Operating CF Margin %	-	-25.97%	-11.12%	-4.43%	-	-	-	-	-	-
Operating CF Growth %	0.08%	-0.43%	0.01%	0.25%	-0.66%	-0.76%	-0.25%	0.44%	0.67%	0.04%
Net Income	-10.62M	-16.95M	-12.3M	-9.86M	-20.46M	-28.77M	-32.47M	-17.87M	-6.91M	-7.52M
Depreciation & Amortization	50K	169K	239K	387K	35K	39K	42K	35K	31K	83K
Stock-Based Compensation	970K	1.63M	1.39M	1.78M	2.23M	2.07M	1.89M	1.3M	892K	531K
Deferred Taxes	-920K	-1.4M	164K	12K	-114K	-437K	84K	0	0	0
Other Non-Cash Items	1.06M	1.67M	-167K	-144K	-63K	-285K	13K	485K	-280K	1.75M
Working Capital Changes	986K	2.75M	-1.4M	-1.21M	3.44M	1.1M	-2.45M	-2.45M	132K	-728K
Change in Receivables	-214K	95K	129K	-63K	-609K	15K	-313K	300K	345K	-192K
Change in Inventory	39K	81K	671K	-142K	609K	-15K	313K	-300K	0	0
Change in Payables	1.38M	863K	-846K	-462K	4.18M	1.05M	-2.17M	-2.31M	-681K	-571K
Cash from Investing+	-11.11M	6.34M	6.44M	-60.02M	6.68M	16.54M	11.46M	17.56M	800K	-1.11M
Capital Expenditures	-159K	-17K	-21K	-90K	-12K	-44K	-11K	-4K	0	0
CapEx % of Revenue	-	0.04%	0.02%	0.04%	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	6M	13K	9K	-6.08M	-21.8M	24.94M	-1K	17.57K	0	-250K
Cash from Financing+	0	4.73M	15.55M	80.18M	143K	768K	17.37M	70K	6.18M	8.79M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	255K	530K	1.03M	143K	61K	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.63M	-12.15M	-12.09M	-9.11M	-14.95M	-26.33M	-32.9M	-18.5M	-6.14M	-5.88M
FCF Margin %	-	-26.01%	-11.14%	-4.47%	-	-	-	-	-	-
FCF Growth %	0.14%	-0.41%	0%	0.25%	-0.64%	-0.76%	-0.25%	0.44%	0.67%	0.04%
FCF per Share	-11.67	-16.02	-14.52	-7.54	-10.62	-18.56	-20.06	-11.04	-26.59	-6.32
FCF Conversion (FCF/Net Income)	0.80x	0.72x	0.98x	0.92x	0.81x	0.95x	1.03x	1.00x	0.89x	0.78x
Interest Paid	0	382K	0	865K	0	0	0	0	0	0
Taxes Paid	0	106K	0	75K	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-40.12%	-103.94%	-91.54%	-19.01%	-23.51%	-48.44%	-85.59%	-84.57%	-50.63%	-49.77%
Return on Invested Capital (ROIC)	-65.09%	-99.83%	-172.49%	-24.17%	-28.44%	-49.42%	-75.57%	-67.38%	49.92%	-41.42%
Gross Margin	-	100%	100%	100%	-	-	-	-	-	-
Net Margin	-	-3630.19%	-1133.55%	-483.61%	-	-	-	-	-	-
Debt / Equity	-	-	-	-	0.01x	0.00x	0.01x	0.00x	0.00x	-
Interest Coverage	-	-251.97x	-252.33x	-255.12x	-678.06x	-974.52x	-764.67x	-82.10x	681.09x	-418.53x
FCF Conversion	0.80x	0.72x	0.98x	0.92x	0.81x	0.95x	1.03x	1.00x	0.89x	0.78x
Revenue Growth	-	-	132.33%	87.83%	-100%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Galmed Pharmaceuticals Ltd. (GLMD) grew revenue by 0.0% over the past year. Growth has been modest.

Galmed Pharmaceuticals Ltd. (GLMD) reported a net loss of $8.7M for fiscal year 2024.

Dividend & Returns

Galmed Pharmaceuticals Ltd. (GLMD) has a return on equity (ROE) of -49.8%. Negative ROE indicates the company is unprofitable.

Galmed Pharmaceuticals Ltd. (GLMD) had negative free cash flow of $5.5M in fiscal year 2024, likely due to heavy capital investments.